ARWR: Encouraging Early Data for Obesity Programs…
By David Bautz, PhDNASDAQ:ARWRREAD THE FULL ARWR RESEARCH REPORTBusiness UpdateEncouraging Early Data for Obesity ProgramsOn January 6, 2026, Arrowhead Pharmaceuticals,…
14,875$
-3,59%
Echtzeit-Aktienkurs Wave Life Sciences Ltd.
Bid:
Ask:
Nachrichten zur Wave Life Sciences Ltd. Aktie
Neues Abnehm-Mittel sorgt für Börsenhype: Wave Life Sciences begeistert mit Fett-weg-und-Muskeln-rauf-Daten
Wave Life Sciences ist ein Biotech-Unternehmen, das an neuartigen RNA-Medikamenten arbeitet. Besonders im Fokus steht gerade ein neues Mittel gegen…
Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company…
Wave Life Sciences Ltd.: PRISM-Plattform und Fortschritte bei der potenziellen Behandlung von Adipositas überzeugen die Analysten!
Wave Life Sciences Ltd. (WVE) ist ein im klinischen Stadium tätiges biopharmazeutisches Unternehmen, das sich auf die Entwicklung von Präzisionsmedikamenten…
Wave Life Sciences surges after early data shows fat loss benefits from experimental obesity drug
Shares of Wave Life Sciences (NASDAQ:WVE) surged more than 126% on Monday after the biotech company reported early clinical data…
Wave Life Sciences: Being Realistic, There Is Still So Much To Prove
…
Wave Life Sciences Ltd. (WVE) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics Transcript
…
Wave Life Sciences Ltd. (WVE): Oppenheimer sieht 175 % Kurspotenzial und verweist auf die Potenziale in der Weiterentwicklung der RNA-Medizin
Wave Life Sciences Ltd. (WVE) hat jüngst mit einer Reihe von vielversprechenden Updates aus ihrer klinischen Pipeline auf sich aufmerksam…
Oppenheimer initiates Wave Life Sciences stock with Outperform rating By Investing.com
Oppenheimer initiates Wave Life Sciences stock with Outperform rating…
Wave Life Sciences: Upgrading Rating To Buy After Turbulent 10 Months
…
Promising Genomics & Synthetic Biology Stocks to Consider in 2025
Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and…
Wave Life Sciences: Potential For Accelerated Approval Pathway With WVE-N531
…
WVE Stock Soars on Upbeat Initial Antitrypsin Deficiency Study Data
Wave Life Sciences stock soars on positive initial data showing the first-ever therapeutic RNA editing in humans in the phase…
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company…
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company…
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company…
Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet
…
Wave Life Sciences Ltd. (WVE) Q2 2024 Earnings Call Transcript
…
Wave Life Sciences Weighty Ambition: Carving Out Obesity Niche
…
RBC maintains $5 target on WAVE Life Sciences shares By Investing.com
RBC maintains $5 target on WAVE Life Sciences shares…
Wave Life Sciences Ltd. (WVE) Q4 2023 Earnings Call Transcript
…
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company…